COST-EFFECTIVENESS OF ANTIPSYCHOTIC DRUGS FOR FIRST- AND SECOND-LINE TREATMENT OF SCHIZOPHRENIA IN BRAZIL
Author(s)
Santos A, Noronha KVMDS, Andrade MV, Ruas CM
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Presentation Documents
OBJECTIVES Considering the low effectiveness of the treatment of schizophrenia and the potential high cost of an inadequate choice, this study aims to conduct an economic evaluation of the list of subsidized antipsychotic drugs in Brazil to allow an adequate choice of pharmacotherapy for the patient and the financial reality of the Brazilian public health system (SUS). METHODS A three-year Markov model with quarterly cycles was developed in TreeAge Pro® 2009 to assess the cost-effectiveness of the first- and second-line treatment of schizophrenia with six antipsychotic drugs - haloperidol, chlorpromazine, risperidone, quetiapine, ziprasidone and olanzapine. Clozapine was indicated as third-line treatment. Outcomes were measured in quality-adjusted life years (QALYs). The perspective of the public health system was adopted. BRL values were converted to PPP-USD using OECD conversion rates. RESULTS 42 different combinations of drugs were evaluated. Only six strategies were not absolutely dominated and, of these, only three were not extendedly dominated. These were chlorpromazine/olanzapine ($7,063 USD; 1.135 QALY), chlorpromazine/risperidone ($8,132 USD; 1.988 QALY) and olanzapine/risperidone ($8,350 USD; 2.055 QALYs). Incremental cost-effectiveness ratios (ICERs) were generally low (chlorpromazine/olanzapine vs. chlorpromazine/risperidone: ICER=1,253 USD/QALY; chlorpromazine/risperidone vs. olanzapine/risperidone ICER=3,254 USD/QALY). Compared to any proposed cost-effectiveness threshold for Brazil, the strategy olanzapine/risperidone would be considered cost-effective. CONCLUSIONS Since olanzapine and risperidone have reasonably different safety profiles and comparable effectiveness, this strategy should be recommended, respectively, for first- and second-line treatment of patients with schizophrenia, who do not have shown previous contraindications to the substances, in SUS.
Conference/Value in Health Info
2019-09, ISPOR Latin America 2019, Bogota, Colombia
Value in Health Regional, Volume 20S (October 2019)
Code
PMH6
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Mental Health